Skip to main content
Premium Trial:

Request an Annual Quote

More Changes at Genset; Cognia Hires For Protein Informatics; Third Wave Adds Management; and others

NEW YORK, June 12-Third Wave Technologies said today that it had added Sam Eletr to the company board of directors.


Eletr, who co-founded Applied Biosystems, was the company's chairman and CEO until 1987. He was also co-founder, chair and CEO of Lynx Therapeutics.


On June 6, the company also announced it had hired a new vice president of business development and a new corporate controller.


Lori Lehman will be VP of business development for the company's genomics unit. She was previously vice president of business development at Argonaut Technologies.


David Nuti has joined the company as corporate controller. He was previously vice president and corporate controller of Fiskars Brands, a consumer product manufacturer.


Third Wave technologies is a publicly traded company based in Madison, Wis.



Epigenomics CEO Alex Olek was awarded the first annual Deutscher Grunderpreis or German StartUp Award last night, the company said.


The award is part of the StartUp Initiative, an effort established by Sparkassen, the German Savings Banks; McKinsey & Company and Stern to promote entrepreneurialism in Germany.


Olek was recognized for the company's work in applying DNA analysis to the detection and treatment of disease.


Epigenomics, which is based in Berlin and has a subsidiary in Seattle, focuses on detecting DNA methylation patterns and applying this information to diagnostics and therapeutics.



Cognia has made three appointments designed to strengthen the company's proteomics information technology efforts, the company said yesterday.


Brian Osborne has joined the company as director of informatics. He was previously in charge of information technology and bioinformatics at Cadus Pharmaceuticals and OSI Pharmaceuticals. He previously worked on genome annotation and bioinformatics in the Arabidopsis genome initiative.


Cognia hired Grace Stafford as curation manager. She was previously in Incyte Genomics' Proteome division, where she worked on a project to annotate mammalian proteome databases.


The company also added Robert Merold to its board of directors. Merold is Executive-in-Residence at Boston Millennia Partners. He was previously chief operating officer at Proteome, which was acquired by Incyte Genomics.



Exelixis said yesterday that it had hired Steven Lacy as senior director of preclinical development.


Lacy will oversee the progress of promising clinical candidates, and help the company develop its rebeccamycin analog cancer drug.


Lacy was previously at Pharmacyclics, and has also worked at Gilead Sciences and ALZA Corporation.



Genomics Collaborative said on June 10 that it had hired Roberto Rodriguez as senior director of business development for genomics and promoted Kevin Krenitsky to the title of senior vice president and medical director.


Rodriguez was previously director of business development for genomic services at Qiagen Genomics. At GCI, he will promote the company's comprehensive repository of DNA, tissue and serum samples.


Krenitsky was previously the company's medical director. In his new role, he will also direct global business development.



Molecular Diagnostics said on June 10 that it had appointed Stephen Wasko as president and chief operating officer and Michael Brodeur as interim chief financial officer.


Wasko will oversee all operations, particularly the company's efforts to expand its cervical cancer screening system. He was previously chief financial and business development officer at Perceptual Robotics, a software firm.


Brodeur will lead financial operations. He is currently partner at Tatum CFO Partners.




Peter Domaille has joined GeneFormatics as director of structural biology, the company said on June 10.


Domaille will direct the company's structural biology programs and NMR development efforts. He will oversee the company's collaborations with various Bruker divisions, primarily focused on using high field NMR spectrometers to determine protein structure.


He was previously director of biomolecular NMR at DuPont Pharmaceuticals.


GeneFormatics is based in San Diego, Calif.



Chemogenomics company Iconix Pharmaceuticals said on June 6 that it had hired James Neal as chief executive officer.


Neal was previously executive vice president for sales, marketing and business development at Incyte Genomics.


He replaces company founder Keith Bostian.


Iconix's main product is a large scale chemogenomic-based informatics system. The company is based in Mountain View, Calif.



The Paris-based genomic drug discovery firm Genset said on June 6 that it had further reorganized its management team.


Former vice president of biopharmaceuticals John Ford will be replaced by Director of Pharmaceutical Development Denis Ravel, who will take over the company's San Diego research center.


General Counsel Jonathan Burnham has left the firm, and is being replaced by Malcolm Bates, who has been with Genset since June 2001 as legal director.


John Lucas, a Genset patent attorney, has been appointed vice president of intellectual property.


Hiroaki Tanaka, who has lead Genset's bioinformatics efforts, has been named vice president of bioinformatics, replacing Robert Abarbanel, who has also left the company.


The management changes follow turnover at the top: In mid-May, Genset co-founder Marc Vasseur took the helm of the company after Andre Pernet resigned as CEO. Chief Financial Officer John Varian left the firm in March.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.